User profiles for Evan M. Bloch
 | Evan BlochAssociate Professor of Pathology, Johns Hopkins University School of Medicine Verified email at jhmi.edu Cited by 7164 |
[HTML][HTML] Deployment of convalescent plasma for the prevention and treatment of COVID-19
Severe acute respiratory syndrome coronavirus 2 (SARS–CoV-2), the cause of coronavirus
disease 2019 (COVID-19), has spurred a global health crisis. To date, there are no proven …
disease 2019 (COVID-19), has spurred a global health crisis. To date, there are no proven …
[HTML][HTML] Sex, age, and hospitalization drive antibody responses in a COVID-19 convalescent plasma donor population
Convalescent plasma is a leading treatment for coronavirus disease 2019 (COVID-19), but
there is a paucity of data identifying its therapeutic efficacy. Among 126 potential …
there is a paucity of data identifying its therapeutic efficacy. Among 126 potential …
[HTML][HTML] Early outpatient treatment for Covid-19 with convalescent plasma
Background Polyclonal convalescent plasma may be obtained from donors who have
recovered from coronavirus disease 2019 (Covid-19). The efficacy of this plasma in preventing …
recovered from coronavirus disease 2019 (Covid-19). The efficacy of this plasma in preventing …
[HTML][HTML] A literature review of Zika virus
AR Plourde, EM Bloch - Emerging infectious diseases, 2016 - ncbi.nlm.nih.gov
Zika virus is a mosquitoborne flavivirus that is the focus of an ongoing pandemic and public
health emergency. Previously limited to sporadic cases in Africa and Asia, the emergence of …
health emergency. Previously limited to sporadic cases in Africa and Asia, the emergence of …
[HTML][HTML] SARS-CoV-2–specific CD8+ T cell responses in convalescent COVID-19 individuals
Characterization of the T cell response in individuals who recover from severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is critical to understanding its …
respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is critical to understanding its …
Comparative performance of five commercially available serologic assays to detect antibodies to SARS-CoV-2 and identify individuals with high neutralizing titers
Accurate serological assays to detect antibodies to severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) are needed to characterize the epidemiology of SARS-CoV-2 …
coronavirus 2 (SARS-CoV-2) are needed to characterize the epidemiology of SARS-CoV-2 …
ABO blood group and COVID‐19: a review on behalf of the ISBT COVID‐19 working group
Growing evidence suggests that ABO blood group may play a role in the immunopathogenesis
of SARS‐CoV‐2 infection, with group O individuals less likely to test positive and group A …
of SARS‐CoV‐2 infection, with group O individuals less likely to test positive and group A …
Minimal Crossover between Mutations Associated with Omicron Variant of SARS-CoV-2 and CD8+ T-Cell Epitopes Identified in COVID-19 Convalescent Individuals
There is a growing concern that ongoing evolution of SARS-CoV-2 could lead to variants of
concern (VOC) that are capable of avoiding some or all of the multifaceted immune response …
concern (VOC) that are capable of avoiding some or all of the multifaceted immune response …
Prevention of transfusion-transmitted infections
Since the 1970s, introduction of serological assays targeting virus-specific antibodies and
antigens has been effective in identifying blood donations infected with the classic transfusion-…
antigens has been effective in identifying blood donations infected with the classic transfusion-…
Clinical practice guidelines from the Association for the Advancement of Blood and Biotherapies (AABB): COVID-19 convalescent plasma
…, N Skoetz, ES Allen, EM Bloch… - Annals of internal …, 2022 - acpjournals.org
Description: Coronavirus disease 2019 convalescent plasma (CCP) has emerged as a potential
treatment of COVID-19. However, meta-analysis data and recommendations are limited. …
treatment of COVID-19. However, meta-analysis data and recommendations are limited. …